$64.53
-0.78-1.19%
Last update: Oct 23, 4:35 PM
Exelixis Inc (EXEL) Stock Price, Quote, News & History
EXELNASDAQ
Exelixis reported final STELLAR-303 data showing a survival trend for zanzalintinib combo in metastatic colorectal cancer patients.
You can purchase shares of Exelixis (NASDAQ:EXEL) through any online brokerage.
Other companies in Exelixis’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Exelixis has a consensus price target of $48.56.
The stock price for Exelixis (NASDAQ: EXEL) is $64 last updated October 23, 2026 at 4:35 PM EDT.
There are no upcoming dividends for Exelixis.
Exelixis does not have any upcoming earnings scheduled.
There is no upcoming split for Exelixis.
Exelixis is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and...
